Inhibition of fibronectin polymerization after experimental ischemic AKI has been shown to attenuate progressive renal fibrosis development in recent work [41], indicating that fibronectin is a potential therapeutic target in the prevention of diclofenac-associated transition of AKI to CKD. This evidence concerns the gene FN1 and acute kidney injury.